- Home
- AGIO vs EXG Comparison
AGIO vs EXG Comparison
Compare AGIO & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- EXG
- Stock Information
- Founded
- AGIO 2007
- EXG 2007
- Country
- AGIO United States
- EXG United States
- Employees
- AGIO N/A
- EXG N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- EXG Finance Companies
- Sector
- AGIO Health Care
- EXG Finance
- Exchange
- AGIO Nasdaq
- EXG Nasdaq
- Market Cap
- AGIO 2.4B
- EXG 2.5B
- IPO Year
- AGIO 2013
- EXG N/A
- Fundamental
- Price
- AGIO $41.33
- EXG $8.53
- Analyst Decision
- AGIO Hold
- EXG
- Analyst Count
- AGIO 5
- EXG 0
- Target Price
- AGIO $52.50
- EXG N/A
- AVG Volume (30 Days)
- AGIO 585.1K
- EXG 533.2K
- Earning Date
- AGIO 10-31-2024
- EXG 01-01-0001
- Dividend Yield
- AGIO N/A
- EXG 8.27%
- EPS Growth
- AGIO N/A
- EXG N/A
- EPS
- AGIO N/A
- EXG N/A
- Revenue
- AGIO $31,306,000.00
- EXG N/A
- Revenue This Year
- AGIO $44.80
- EXG N/A
- Revenue Next Year
- AGIO $174.95
- EXG N/A
- P/E Ratio
- AGIO N/A
- EXG N/A
- Revenue Growth
- AGIO 55.39
- EXG N/A
- 52 Week Low
- AGIO $19.80
- EXG $6.78
- 52 Week High
- AGIO $53.29
- EXG $8.15
- Technical
- Relative Strength Index (RSI)
- AGIO 37.77
- EXG 53.59
- Support Level
- AGIO $40.37
- EXG $8.50
- Resistance Level
- AGIO $46.24
- EXG $8.72
- Average True Range (ATR)
- AGIO 2.35
- EXG 0.09
- MACD
- AGIO -0.66
- EXG 0.00
- Stochastic Oscillator
- AGIO 7.39
- EXG 36.67
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks with an emphasis on dividend-paying stocks and writes call options on one or more U.S. and foreign indices with respect to a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.